[Objective] To explore the clin. efficacy and safety of Shugan Jieyu capsule combined with mosapride in the treatment of slow transit constipation (STC). [Method] 84 cases of STC patients meeting Rome III diagnostic criteria were randomly divided into a test group and a control group. 42 cases in the test group were treated with Shugan Jieyu Capsule combined with mosapride, and 42 cases in the control group were treated with mosapride alone, the course of treatment was 6 wk. The constipation symptom score, Zung Self-Rating Depression Scale (SDS), and Zung Self-Rating Anxiety Scale (SAS) were used to evaluate the efficacy of the two groups. [Result] Before treatment, 3 weekends of treatment and 6 weekends of treatment, the total scores of constipation symptoms in the exptl. group were (13.87±3.11) points, (9.61±2.32) points, and (4.01±2.17) points, resp., the differences within the group were statistically significant (P<0.05); The total scores of constipation symptoms in the control group were (13.02±2.90) points, (10.08±2.11) points, and (9.54±2.0i) points. There were statistically significant differences between the 6 wk of treatment and before treatment (P<0.05). There was a statistically significant difference between the exptl. group and the control group for 6 wk of treatment (P<0.05). The SDS and SAS scores of the test group before treatment, 3 wk of treatment, and 6 wk of treatment were (52.14±6.37), (48.10±7.01), and (46.32±8.21) points, resp., and (48.17 ± 7.78) points, (43.38 ± 6.89) points, (40.18 ± 9.97) points, the difference was statistically significant (P<0.05). The control group was resp. (51.87±5.89) points, (51.64±8.31) points, (49.57±6.07) points and (47.05±8.40) points, (45. 92±8.98) points, (44.78±7.30) points, and the differences were not statistically significant (P>0.05). There were statistically significant differences in SDS and SAS scores between the two groups during the 6th week of treatment (P<0.05). [Conclusion] Shugan Jieyu Capsule can effectively improve the anxiety and depression of STC patients. The clin. effect of the combined use of Shugan Jieyu Capsule and mosapride in the treatment of STC is better than that of mosapride alone.